This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Jun 9, 2026

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

Seeking Alpha • Jun 8, 2026

West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Seeking Alpha • Jun 2, 2026

West Pharma names former Thermo Fisher executive Lagarde as CEO

West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel ​Lagarde as its top boss, effective ‌August 31, succeeding longtime chief Eric Green.

Reuters • Jun 1, 2026

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.

PRNewsWire • Jun 1, 2026

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services, Inc.  WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.

Zacks Investment Research • May 21, 2026

West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast

West Pharmaceutical Services said on Wednesday it has ​restored operations across its sites after a cybersecurity attack earlier this ‌month and expects the incident to have no material impact on its 2026 financial outlook.

Reuters • May 20, 2026

My Top Dividend Growth Picks In Each GICS Sector

I present my top dividend growth picks for each of the 11 GICS sectors, emphasizing discounted valuations and safe, growing dividends. The Sector Winners portfolio outperformed SPY with a 333% five-year return (ex-dividends) and a 0.9% yield; Runners-Up returned 83% with a 1.3% yield. I use a rigorous quality scoring system and sector diversification to minimize dividend cut risks and optimize portfolio resilience.

Seeking Alpha • May 19, 2026

West Pharma says operations recovering after cyberattack

West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack ​earlier this month disrupted manufacturing and logistics ‌globally.

Reuters • May 15, 2026

Investors Await Damage Assessment After West Pharmaceutical Cyberattack

West Pharmaceutical Services Inc. (NYSE:WST) on Monday disclosed a material cybersecurity attack on May 7, saying an unauthorized party exfiltrated data and encrypted certain systems.

Benzinga • May 12, 2026